Atrial fibrillation is associated with increased risk of fatal and non-fatal cardiovascular events in patients with heart failure and preserved ejection fraction findings from the irbesartan in heart failure with preserved systolic function trial (I-PRESERVE) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Zile, Michael R
  • Komajda, Michel
  • McKelvie, Robert
  • McMurray, John
  • Donovan, Mark
  • Ptaszynska, Agata
  • Carson, Peter
  • Massie, Barry M

publication date

  • October 16, 2007